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Abstract
Background
Conflicts of interest in biomedical research can influence research results and drive
research agendas away from public health priorities. Previous agenda-setting studies share
two shortfalls: they only account for direct connections between academic institutions and
firms, as well as potential bias based on researchers’ personal beliefs. This paper’s goal is
to determine the key actors and contents of the prevailing health and biomedical sciences
(HBMS) research agenda, overcoming these shortfalls.
Methods
We performed a bibliometric and lexical analysis of 95,415 scientific articles published
between 1999 and 2018 in the highest impact factor journals within HBMS, using the Web
of Science database and the CorText platform. HBMS’s prevailing knowledge network of
institutions was proxied with network maps where nodes represent affiliations and edges
the most frequent co-authorships. The content of the prevailing HBMS research agenda
was depicted through network maps of prevalent multi-terms found in titles, keywords, and
abstracts.
Results
The HBMS research agendas of large private firms and leading academic institutions are
intertwined. The prevailing HBMS agenda is mostly based on molecular biology (40% of the
most frequent multi-terms), with an inclination towards cancer and cardiovascular research
(15 and 8% of the most frequent multi-terms, respectively). Studies on pathogens and
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biological vectors related to recent epidemics are marginal (1% of the most frequent multi-
terms). Content of the prevailing HBMS research agenda prioritizes research on pharmaco-
logical intervention over research on socio-environmental factors influencing disease onset
or progression and overlooks, among others, the study of infectious diseases.
Conclusions
Pharmaceutical corporations contribute to set HBMS’s prevailing research agenda, which is
mainly focused on a few diseases and research topics. A more balanced research agenda,
together with epistemological approaches that consider socio-environmental factors associ-
ated with disease spreading, could contribute to being better prepared to prevent and treat
more diverse pathologies and to improve overall health outcomes.
Introduction
The influence of industry over scientific research raises many debates, particularly when it
comes to setting research agendas. Some empirical analyses found that collaborations between
industry and university generate a skewing problem (or dilemma), by creating a bias in aca-
demic agendas towards private needs [1,2]. Other authors argued, on the contrary, that
agendas have not been significantly skewed due to the commercialization of research and its
outcomes [3–5].
Regardless of their different results, all previous investigations share two problematic fea-
tures. First, their chosen methodology is either based on surveys or interviews with different
stakeholders (such as researchers and university authorities) or consists of case studies. Search-
ing for a skewing problem by analysing researchers’ impressions presents a shortfall since, as
was observed by Kleinman and Vallas [6], surveyed or interviewed researchers may ignore
external influences that affect their research agenda. Second, they look at the explicit influence
of research commercialization on the determination of academic research agendas by analys-
ing direct links with private corporations (through private sponsorship of academic research,
agreements, exchanges in academic events, or other informal knowledge transfers, among
others). This approach may cause the interests of corporations to influence the non-directly
related research agendas of academic institutions. For instance, when a leading academic insti-
tution establishes direct links with both private stakeholders and other academic institutions,
the institution may end up unwillingly transferring the research priorities of the former to the
latter.
In the specific case of medical research, there is a more unanimous agreement on the
impact of industry sponsorship and conflicts of interest in medical research and clinical prac-
tice, which ultimately influence research results [7–9]. A different question, however, is if, and
the extent to which private firms can influence research agendas and set priorities in the pre-
vailing network of medical knowledge production. Fabbri et al. offered an in-depth review of
medical literature, showing that corporate interests can drive research agendas away from
issues that are more relevant to public health [10]. Previous studies also show that the pharma-
ceutical industry’s expenses on marketing and promotional activities predominate over
research and development (R&D) expenses [11]. Unsurprisingly, corporations tend to fund
research in areas that guarantee a large market share. This is able to explain examples such as
pharmaceutical companies being more likely to sponsor studies on diseases that affect high-
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income countries [12,13]. Whether this corporate influence over academic research agendas
represents a phenomenon observed at the margin of health and biomedical sciences (HBMS)
investigations or sets the prevailing HBMS research agenda remains an open question. We
addressed this question with an interdisciplinary approach, building on the theoretical concept
of agenda from the agenda-setting theory [14]. This theory focuses on the salience of objects
(things that an individual has an attitude or an opinion about) within media discourse and the
consequences that this has on general public agendas. The proposed study focuses on the con-
tent of these agendas, rather than the efforts to dictate them (e.g., in our case, public policies
regarding HBMS) and the projection of that kind of study to different agendas in contempo-
rary society [14]. This way, we are able to reconstruct a specific agenda from the different levels
of presence that different topics have in the outcome of a practice, in this case, the presence of
different terms associated with problems and methodologies in HBMS scientific research.
The field of HBMS constitutes a model case of blurred boundaries between academic and
commercial research [15], and thus represents an ideal system to investigate the centrality of
corporate interest on the prevailing research agenda. This analysis is especially relevant in the
context of the exhaustion of the blockbuster business model and the recent transformation of
innovation strategies focusing on specialized medicine, in which pharmaceutical companies
intensified the outsourcing of certain stages of their R&D process [16–18]. As a result, large
pharmaceuticals organize, steer, and ultimately control global innovation networks, where
leading universities and other academic research organizations are active participants [19,20].
To proxy the HBMS research agenda, and search for a potential influence of private corpo-
rations in setting that agenda, we analysed scientific publications, the most common academic
research outcome. Within the overall set of publications in a field, those in high-impact factor
journals exert the greatest influence in terms of that field’s research priorities. Therefore, we
defined the “prevailing HBMS research agenda” as the agenda characterized by the prevalent
multi-terms found in the 30 journals with the highest impact factors within the HBMS field.
This approach allowed us to identify key actors and contents of that agenda, excluding previ-
ous shortfalls, as well as to examine three issues: (1) Whether private corporations participate
in the HBMS’s prevailing network of research organizations; (2) Whether the prevailing
HBMS research agenda involves the study of a diversity of diseases, or if there is an inclination
toward specific ones; and (3) Whether the prevailing HBMS research agenda involves a plural-
ity of research topics and methodologies.
Materials and methods
Search strategy and selection criteria
To conduct our investigation, we retrieved a corpus of HBMS scientific publications from
Web of Science (WoS) that proxies the prevailing HBMS research agenda. WoS classifies jour-
nals in terms of scientific categories, so we manually selected all the specific categories that cor-
responded to HBMS (listed in S1 Table legend). Next, we retrieved the full list of journals that
corresponded to any of those specific categories and selected the 30 journals with the highest
impact factors. For the selected journals, we retrieved all available publications (including orig-
inal research articles, reviews, perspectives, editorials, etc.) between 1999 and 2018: 96,045
papers, out of which we were able to analyse 95,415 (those articles from which we could not
gather all the required information or displayed errors during processing—0.7% from the total
—were filtered). This provided a corpus to investigate the prevailing HBMS research agenda.
To assess the temporal evolution of this research agenda, we split the corpus into two regu-
lar sub-periods: 1999–2008 and 2009–2018. The sub-periods were relatively homogeneous in
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terms of the number of publications (47,958 and 47,457 papers, respectively), indicating that
the publishing frequency of top journals remained stable.
Data analysis
The data was processed using the CorText platform [21], which allowed us to build co-occur-
rence maps. These maps were constructed by using specific algorithms that associate entities
(names of research institutions and most frequent terms) according to their frequency of co-
occurrence within a chosen corpus of texts [22]. In our analysis, the corpus consisted of a set
of scientific publications. The procedure used to draw these maps, including the filtering of the
corpus, followed the methodology presented in Tancoigne et al. [21].
Given our research question, we followed a two-step process: 1) we reconstructed the
HBMS network of prevailing publishing institutions, defined as those that co-occurred with
the highest frequency as authors’ affiliations in our corpus, and 2) we analysed the prevailing
content of the research included in our corpus, proxying the prevailing research agenda. For
each step, we introduced a dynamic component by considering the two mentioned periods. A
step-by-step methodology is provided in the following section.
1) Reconstruction of the prevailing HBMS knowledge network. Unlike other biblio-
metric databases, the WoS provides a separate field with authors’ affiliations called “research
institution”. For each of the two selected periods, we used this field to map the most frequently
connected affiliations.
To build these network maps, we based our methodology on previous work. These previous
studies showed that social network analyses using co-patenting and co-publication data allow
for mapping relations between actors within a knowledge or innovation system [23,24]. This
has become a standard way of measuring science-industry collaborations [25]. Cooke [26], for
example, analysed top impact factor journals from HBMS to proxy its prevailing knowledge
network. However, this study focused on the geographical distribution of this network, over-
looking the specific actors involved and their research agenda(s).
Although the WoS presents an already cleaned database, affiliations frequently appeared
spelled differently. To build a harmonized list, thus assuring that each institution appeared
under only a single name, we followed the methodology presented in Tancoigne et al. [21].
First, we listed all institutions in alphabetical order and created a new field with a unified affili-
ation for each institution. We defined special criteria to determine each type of institution. In
our retrieved corpus, each university was renamed as “univ” followed by the rest of its name in
English. University hospitals and schools were renamed after the name of their corresponding
university. For all the hospitals with names that did not indicate a university affiliation, we
searched on Wikipedia and the hospital’s website to find possible affiliations. To unify the
names of private firms when they appeared as affiliations, we worked with companies’ (in par-
ticular large pharmaceuticals) corporate trees, as provided by Derwent Innovation. Further-
more, in the United States (US), United Kingdom (UK) and France, some institutions belong
to a “university system” (called COMUE in France). As a result, many researchers only include
their university system affiliation and others add the name of their particular institution within
that grouping. To have a unified criterion for every organization and considering the corpus
limitations (it was not always possible to disentangle the institutions), we followed Rikap [20]
and merged all the affiliations at the level of the corresponding parent organization.
The simplest network of research collaboration between institutions appearing in the field
“research institutions” in our corpus would have been one that considers all the institutions that
have collaborated at one time or another as connected by a link. But the resulting network
would have been too dense and not very informative. Since we wanted to focus on the most
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influential institutions (defined as those with the highest publishing frequency at each time
period), we prioritized the top 200 nodes or vertices. To weight the network’s links, we used
chi-square proximity measure to determine nodes and edges to be considered in each network
map. Hence, the applied chi-square metric to construct the co-occurrence matrices of each of
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Chi-square is a direct local measure, meaning that it considers actual occurrences between
entities. Indirect measures, such as the distributional one, build network maps based on the
similarity of two nodes in comparison with their entire co-occurrence profile with the other
identified entities [21]. Hence, they should not be applied in our case because our research
question requires looking for actual links. Chi-square normalization tends to create links
towards higher degree nodes. Therefore, this metric prioritizes the most frequent co-occur-
rences within the network and those are the direct ties (edges). Applied to our corpus, using
the chi-square measure creates direct connections only for the most frequently co-authoring
institutions from total co-authorships.
Next, we used the Louvain community detection algorithm as our cluster detection method
[27]. A cluster means that in relation to the rest of the edges, those within the cluster represent
the most frequent co-occurrences of the nodes that belong to that cluster.
In the resulting maps (Figs 1 and 2), the nodes represent institutions (universities, research
bodies, enterprises, etc.). The size of the nodes represents the frequency of each institution’s
appearance in the dataset (thus each institution’s publishing frequency for selected journals).
As previously explained, we used chi-square, which is a normalized proximity measure that
creates links (edges) towards higher degree nodes. Edges connecting nodes or vertices repre-
sent the most frequent (but not all) co-authorships. When two nodes were indirectly linked by
a third node, in the network, this third institution occupied a bridging position.
A standard measure for considering the intermediating role of each node in a network is
that of betweenness centrality, defined as the sum of the ratio of the shortest paths between
any two nodes in the network that pass through that node. We calculated this measure using
Gephi and considered it to evaluate the position of the large pharmaceuticals that appeared in
Figs 1 and 2. Besides this measure, since we grouped nodes in clusters, we were also interested
in the number of clusters that a single node connects as an indicator of a research institutions’
influence in the overall network. A node could have a high betweenness centrality but only
because it occupies a central position inside its cluster. In this case and considering our
research problem, that research institution could be interpreted as having a high influence in
setting the research agenda of its cluster, but the measure would not say much of its chance of
transferring its R&D priorities to the general network. This is why we complemented this mea-
sure with an analysis of the number of edges, in particular edges with nodes from different
clusters, considering the latter as bridges between clusters.
Nodes occupying bridging positions connecting different clusters are of particular rele-
vance for holding the clusters together and “in the dynamics of spreading processes across the
PLOS ONE Whose shoulders is health research standing on?
PLOS ONE | https://doi.org/10.1371/journal.pone.0249661 April 7, 2021 5 / 17
Fig 1. Top 200 health and biomedical sciences (HBMS) research affiliations (1999 to 2008) plotted according to co-authorship using a chi-squared distribution.
Source: Authors’ analysis based on Web of Science (WoS) data extraction plotted via CorTexT.
https://doi.org/10.1371/journal.pone.0249661.g001
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network” [28]. Bridges represent channels through which research priorities can be established
and disseminated in both directions. If a public institution or a private firm occupies a bridg-
ing position, it will have a better chance of transferring its R&D priorities to the general net-
work. In other words, the chances of exerting indirect influence will be greater in a bridging
position than in a position with very few edges within the same group.
Fig 2. Top 200 HBMS research affiliations (2009 to 2018) plotted according to co-authorship using a chi-squared distribution. Source: Authors’ analysis based on
WoS data extraction plotted via CorTexT.
https://doi.org/10.1371/journal.pone.0249661.g002
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The resulting network maps -one for each period- can be conceived as a proxy of HBMS’s
prevailing knowledge network of organizations.
2) Reconstruction of HBMS top journals’ research agenda. The definition of “agenda”
that we have used conceives agendas as flowing from the set of prevailing topics shared by a
community. In our case, the agenda is defined as the prevailing topics of the HBMS research
community. Furthermore, by focusing on top journals by impact factor to proxy this agenda,
we are assuming that topics most frequently studied in these journals’ publications influence
the overall HBMS research community. In other words, we assume a normative influence of
high impact factor journals over the whole research community within a research field [29,30].
Since these journals have the highest impact factors, it means that on average, each journal’s
publications are the most cited ones. This is an indication of their greater relative influence
within the HBMS field.
To build the prevailing HBMS research agenda, we performed a lexical analysis of the titles,
keywords, and abstracts of the full HBMS high-impact factor journals’ corpus. We extracted
the top 500 multi-terms of up to 5 words as a proxy of privileged topics. Monograms were
excluded, and each list was refined following an in-depth cleaning process. This filtering was
performed to avoid words not related to the HBMS field and whose frequency responds to
either their grammatical function (such as “and” and “or”) or the level of grammaticalization
within the scientific genre (“methods and results”, “case study”, “present study”, “positive
effect”, etc.). The resulting list of 320 multi-terms was classified into general categories accord-
ing to research topics (such as “Cancer/Tumor” or “Cardiovascular”). During the process of
selecting the key multi-terms, we found that many were linked to methods and procedures.
We decided to include them, as they provide valuable data on the nature of the research
under analysis. For instance, a paper may contain terms such as “polymerase chain reaction”
or “electron microscopy” in its title and/or abstract, which may indicate that the topic is being
studied from a molecular and cellular biology perspective and/or using tools associated with
this specialty.
A network map was built for each period, plotting its corresponding most frequently con-
nected multi-terms, following the same procedure used for research institutions’ network
maps. In this case, nodes represented multi-terms. We prioritized the top 100 for each period
(similar overall results were obtained selecting the top 150 multi-terms for each period). These
maps also included the general categories’ classification that we made as a third depicted vari-
able. We plotted the top three general categories associated with each cluster. We inferred that
the most frequently connected multi-terms corresponded to those research topics and meth-
odologies that define the prevailing HBMS research agenda. As explained by Barbier et al. [22],
“co-word analysis maps various types of associations between terms that ontologically repre-
sent the textual strategizing of authors is a method that extracts data from texts without pre-
sumptions about their content”. For the same reasons explained above, we also used chi-
square to determine the edges of the multi-terms’ network maps and the Louvain algorithm to
detect clusters.
Results
HBMS prevailing network of knowledge production
To proxy the HBMS prevailing research agenda and to identify the possible presence of corpo-
rate influence, we applied bibliometric and lexical analysis techniques to a corpus of 95,415
scientific publications from the 30 highest impact factor journals within HBMS (S1 Table)
between 1999 and 2018. Briefly, we assessed the number of publications authored by each
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organization and mapped the most frequently connected co-authors’ affiliations in this corpus
of scientific publications.
Our results show that HBMS’s prevailing network of research organizations is led both by
prominent academic research institutions and large pharmaceutical corporations (Figs 1 and
2; S2 Table). This means that these corporations are among the top 200 organizations in terms
of co-occurrence frequency in our corpus of the 30 journals with the highest impact factors
within the HBMS field. As we show in Fig 1, where we consider co-authorship frequency for
the first period (1999–2008), there are large pharmaceutical corporations among the HBMS’s
prevailing network of research organizations, namely: Roche, Merck, Novartis, AstraZeneca,
and GlaxoSmithKline (Fig 1).
In the second period (2009–2018), Merck and AstraZeneca disappear from the network,
and Pfizer and Amgen show up (Fig 2). In comparison with the first period, large pharmaceu-
tical companies increased connections with other institutions of the network -from 15 total
direct links (3 on average) to 32 (6 on average)- pointing to a growing capacity to influence
HBMS’s prevailing research agenda. Particularly, Roche’s bridging position in the second
period stands out. First, its betweenness centrality went from 0 in the first period to 0.003 in
the second period. This change represented a higher rank according to this measure, and thus
a relatively greater intermediator role. Second, from having only one direct link within the
same cluster (Fig 1), Roche connects with 11 institutions from 4 different clusters in the second
period (Fig 2). This result is of particular relevance if we consider, for instance, that in the
same period the University of London, that has the 3rd highest betweenness centrality (0.062),
was directly connected to nodes corresponding to 3 different clusters. Moreover, Novartis was
ranked 112 in betweenness centrality in the first period and 57 in the second (from 0.0058 to
0.0089).
The ranking of organizations in terms of overall publishing frequency in distinct docu-
ments provides similar results for the whole period (1999–2018). Roche, GlaxoSmithKline, Pfi-
zer, and Merck together with Amgen Inc. occupy positions between the 64th and the 200th (S2
Table).
In terms of the geopolitical distribution of HBMS’s prevailing knowledge network, leading
countries and regions stand out. In the first period, different clusters can be associated with a
variety of countries. However, 4 clusters (a 25% overall) are linked to the US (this means that
most of the nodes correspond to US-based organizations). Particularly, Roche and Novartis
always appear in US-dominated clusters even if they are Swiss in origin. Within Europe, the
UK, Germany, France, Italy, Netherlands, Switzerland, Belgium, Sweden, and Denmark pre-
dominate (Fig 1).
In the second period, the US (36%), the UK (11%), Germany (10%), and France (6%) con-
centrate over 60% of total institutions. Other 25 countries are represented in the correspond-
ing map, but with marginal participation (Fig 2). Seven of the top ten publishing organizations
throughout our whole study period are based in the US according to their publishing fre-
quency (S2 Table). The world’s top two organizations are Harvard and the University of
California (12,067 and 11,090 different scientific publications between 1999 and 2018, respec-
tively). They each occupy a central position in a different cluster and occupy bridging network
positions in both periods (S2 Table). The top ten is completed with two universities from the
UK (the University of London in the 3rd position, and Oxford University in the 9th position)
and one from Germany (the Max Planck Institute, in the 10th place).
The overall number of publishing institutions grew around 75% between periods (from
18,965 to 33,117). In both periods, around 65% of the institutions published only one paper
in HBMS’s top 30 journals. However, at least one of the top 200 institutions was among the
authors of 91% and 81% of the papers, in the first and second period, respectively. The network
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shows a reduction in the total number of clusters (from 12 to 7) between periods. There is also
an increase in the number of links between clusters (Figs 1 and 2), showing that the scientific
production in HBMS is becoming more unified and revolving around a group of leading orga-
nizations from core countries.
Prevailing HBMS research agenda
Next, we assessed the most prevalent terms found in titles, keywords, and abstracts in this cor-
pus of scientific publications. In both periods, as much as 40% of the most frequent multi-
terms derived from the analysed publications are related to general categories linked with
molecular and cellular levels such as “protein kinase”, “monoclonal antibody”, “RNA interfer-
ence”, or “epidermal growth factor receptor” (S3 Table). We also found that terms linked to
cancer research, such as “cancer cells” and “tumor growth”, were preponderant (Figs 3 and 4,
green circles). Noteworthy, six of the 30 journals with the highest impact factor within the field
of HBMS are focused on oncology. Consistently, nearly 15% of the most frequent multi-terms
in different documents were classified as related to cancer (S3 Table). In the second period, the
predominance of cancer multi-terms increases, and they split into two separate clusters (Fig 4,
green circles).
The second most prevalent general category related to a specific group of human diseases is
cardiovascular. Both periods present a cluster dominated by multi-terms associated with this
general category (Figs 3 and 4, lilac circle), as evidenced by the emergence of terms like “car-
diac death” and “coronary heart disease”. In total, 8% of the most frequent multi-terms are
associated with this general category (S3 Table).
Other less prevalent multi-terms integrate different clusters associated with neurological
diseases and mental health, immunology, metabolic syndromes (such as diabetes), or bone
research (Figs 3 and 4). Finally, there are two small and barely connected clusters in the first
period associated with environmental terms (yellow circle) and pathogens (salmon circle). In
the latter, the Human Immunodeficiency Virus (HIV) is the only mentioned pathogen (Fig 3).
Moreover, these clusters disappear entirely in the second period (Fig 4). Consistently, only 1%
or less of the most frequent multi-terms in different documents are associated with general cat-
egories such as pathogens, microbiology, or environmental (S3 Table).
Discussion
We presented data supporting the hypothesis that the research agendas of large pharmaceutical
firms are intertwined with those of leading academic institutions concentrated in specific
countries, which is consistent with the findings of previous studies [15]. Roche, GlaxoSmithK-
line, Pfizer, Merck, AstraZeneca, and Amgen Inc. participate in the prevailing HBMS knowl-
edge network of organizations, and their influence (number of connections with other
institutions of the network) has increased in the last ten years. Given the latter, we can infer
that at least part of their research agenda is embedded in the prevailing HBMS research
agenda. This allows the possibility of pharmaceutical firms influencing the HBMS research
field beyond their direct collaborations with academics. As explained previously, the skewing
problem was defined as the tension between academic and commercially oriented research
[1,2]. Therefore, our findings provide evidence about the existence of a skewing problem irre-
spective of direct links with private companies and regardless of researchers’ awareness. More-
over, in line with Rikap [20], large pharmaceutical corporations tend to be directly linked and
some of them even belong to the same cluster, thus favouring the thesis of technological coop-
eration between large pharmaceutical companies in certain steps of their respective innovation
networks.
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In terms of the geopolitical distribution, we found a predominance of North America (in
particular, the US) and Europe. Beyond these regions, Australia, China, Japan, and Israel have
between three and seven institutions participating in the prevailing HBMS knowledge net-
work. While there is a majority of US institutions, scientific production in HBMS is becoming
more unified and spinning around a group of leading organizations from a core of countries.
Our results suggest that the prevailing HBMS research agenda is dominated by a perspec-
tive where medical knowledge is mostly based on research in the field of molecular biology.
This claim is supported by the prevalence of terms and topics associated with molecular and
cellular biology. Moreover, it prioritizes cancer and cardiovascular research over other pathol-
ogies. This prevalence is revealing in terms of the topics that are not part of this agenda. While,
Fig 3. Top 100 HBMS research multi-terms (1999 to 2008) plotted according to co-occurrence using a chi-squared distribution. Source: Authors’ analysis based on
WoS data extraction plotted via CorTexT.
https://doi.org/10.1371/journal.pone.0249661.g003
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by definition, neglected diseases are absent from the agenda, it is significant that research on
pathogenic viruses, bacteria or other microorganisms, and biological vectors (for example,
bats) is marginal. Although it is difficult to assess, it is conceivable that if these topics would
have had a more prevalent place in the high-impact factor journals’ agenda, resulting knowl-
edge would have been a very valuable background to prevent or treat epidemics and pandem-
ics in a more effective way [31]. It is also meaningful to observe that research on prevention,
social determinants of health, and assessment of socio-environmental factors influencing dis-
ease onset or progression is negligible. Overall, the main focus of the prevailing HBMS agenda
appears to be set on therapeutic and specifically pharmacological intervention involving the
Fig 4. Top 100 HBMS research multi-terms (2009 to 2018) plotted according to co-occurrence using a chi-squared distribution. Source: Authors’ analysis based on
WoS data extraction plotted via CorTexT.
https://doi.org/10.1371/journal.pone.0249661.g004
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use of novel drugs or innovative molecular biology techniques. At the same time, prevention
and assessment of socio-environmental factors influencing disease onset are almost absent.
As Kaiser described, reductive explanations refer to factors at a lower level than the phe-
nomenon at issue; they concentrate on internal factors and thus ignore or simplify the envi-
ronment of a system, studying only the parts of an isolated system [32]. In the case of cancer,
our results point to a research strategy that ignores the growing evidence of carcinogenicity
associated with different environmental pollutants derived from technoscience and related
to human activities [33]. While cancer and cardiovascular diseases are among the top ten
causes of death worldwide and therefore an enrichment in multi-terms related to research
in these disorders was expected, it is noteworthy that other highly prevalent causes of death,
including respiratory, diarrhoeal, and infectious diseases are severely underrepresented in the
prevailing agenda [34,35]. The fact that our results reveal a growing prevalence of cancer in the
prevailing HBMS research agenda should not be surprising. Large pharmaceutical corpora-
tions announced a shift towards more profitable diseases such as cancer around ten years ago
[36]. As previously reported, the anticancer drugs’ market is highly profitable, even for drugs
that represent little or no additional therapeutic value to the population [37–39].
Summing up, one of the main contributions of this article is to approach the skewing
dilemma from a novel methodology that enlarges the scope of existing research, overcoming
its shared shortfalls. To our knowledge, there is no background of an investigation on the
skewing problem that simultaneously provides evidence beyond direct links with private firms
and the perceptions of the actors involved. Our contribution addresses all the latter by map-
ping bibliometric evidence and revealing the network of power relationships that underlies the
prevailing HBMS research agenda.
Nonetheless, a significant limitation of our research is that we have only considered one
academic research outcome (publications). Our results may end up favoring topics within
HBMS that are more often published as papers over other outcomes, such as reports for public
authorities, patents, or the creation of a spin-off. Another limitation is that we did not look at
the interplay between co-authorship and funding sources. It was shown by previous literature
that industry influences HBMS research by sponsoring certain topics and methods [7–9].
Therefore, we may expect both factors to complement each other. More research will be
needed to shed light on these aspects. Our future agenda includes this research question.
Additionally, the journal selection process may be considered as another limitation of this
study, since it could play a role in creating a bias due to a sampling process focused on a lim-
ited set of journals, those with the highest impact factor. Although preliminary data using dif-
ferent sets of high impact journals showed similar results, further research will be necessary to
address whether these results can be extrapolated to other journals within the field. In this
sense, this work concludes only on what we defined as the prevailing HBMS research agenda,
drawn from the 30 journals with the highest impact factor within the field of HBMS. However,
it is worth emphasizing that our analysis included some of the most influential interdisciplin-
ary scientific journals and particularly some of the most prestigious journals specialized in
microbiology or infectious diseases.
Since we found that certain large pharmaceutical corporations contribute to set HBMS’s
prevailing research agenda, further research will also involve comparing the research agendas
of these corporations—defined by their scientific publications—with the prevailing HBMS
research agenda obtained from our analysis. This will allow us to provide evidence on their
level of alignment. Finally, further investigations will also explore the global implications of
the lack of diversity, since we found that HBMS’s prevailing research agenda is mainly focused
on a few diseases and research topics. A more balanced research agenda, together with episte-
mological approaches that consider socio-environmental factors associated with disease
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spreading, could contribute to being better prepared to prevent and treat more diverse pathol-
ogies and to improve overall health outcomes.
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